CN101687858B - 作为多巴胺-β-羟化酶抑制剂的1,3-二氢咪唑-2-硫酮衍生物 - Google Patents

作为多巴胺-β-羟化酶抑制剂的1,3-二氢咪唑-2-硫酮衍生物 Download PDF

Info

Publication number
CN101687858B
CN101687858B CN2008800151606A CN200880015160A CN101687858B CN 101687858 B CN101687858 B CN 101687858B CN 2008800151606 A CN2008800151606 A CN 2008800151606A CN 200880015160 A CN200880015160 A CN 200880015160A CN 101687858 B CN101687858 B CN 101687858B
Authority
CN
China
Prior art keywords
compound
inhibitors
compound according
formula
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800151606A
Other languages
English (en)
Chinese (zh)
Other versions
CN101687858A (zh
Inventor
帕特里西奥·曼努埃尔·维埃拉·阿劳若·苏亚雷斯·达席尔瓦
戴维·亚历山大·李尔曼斯
亚历山大·别利亚耶夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Bial Portela and Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38198874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101687858(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial Portela and Cia SA filed Critical Bial Portela and Cia SA
Publication of CN101687858A publication Critical patent/CN101687858A/zh
Application granted granted Critical
Publication of CN101687858B publication Critical patent/CN101687858B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2008800151606A 2007-05-08 2008-05-06 作为多巴胺-β-羟化酶抑制剂的1,3-二氢咪唑-2-硫酮衍生物 Expired - Fee Related CN101687858B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds
GB0708818.0 2007-05-08
PCT/PT2008/000019 WO2008136695A1 (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase

Publications (2)

Publication Number Publication Date
CN101687858A CN101687858A (zh) 2010-03-31
CN101687858B true CN101687858B (zh) 2012-12-26

Family

ID=38198874

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800151606A Expired - Fee Related CN101687858B (zh) 2007-05-08 2008-05-06 作为多巴胺-β-羟化酶抑制剂的1,3-二氢咪唑-2-硫酮衍生物

Country Status (29)

Country Link
US (5) US8481582B2 (enExample)
EP (1) EP2155731B1 (enExample)
JP (1) JP5559677B2 (enExample)
KR (1) KR101598482B1 (enExample)
CN (1) CN101687858B (enExample)
AR (2) AR066457A1 (enExample)
AT (1) ATE499367T1 (enExample)
AU (1) AU2008246443B2 (enExample)
BR (1) BRPI0811275B8 (enExample)
CA (1) CA2686387C (enExample)
CL (1) CL2008001321A1 (enExample)
CY (1) CY1111517T1 (enExample)
DE (1) DE602008005141D1 (enExample)
DK (1) DK2155731T3 (enExample)
ES (1) ES2360841T3 (enExample)
GB (1) GB0708818D0 (enExample)
HR (1) HRP20110253T1 (enExample)
IL (1) IL201921A (enExample)
MX (1) MX2009012041A (enExample)
NO (1) NO20093275L (enExample)
NZ (1) NZ580962A (enExample)
PL (1) PL2155731T3 (enExample)
RS (1) RS51692B (enExample)
RU (1) RU2501796C2 (enExample)
SI (1) SI2155731T1 (enExample)
TW (1) TWI458722B (enExample)
UA (1) UA104844C2 (enExample)
WO (1) WO2008136695A1 (enExample)
ZA (1) ZA200908612B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
US9212130B2 (en) * 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
RU2604734C2 (ru) * 2010-12-22 2016-12-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Кристаллическая форма и способ ее очистки
US9346751B2 (en) 2011-06-29 2016-05-24 Bial-Portela & Ca, S.A. Process for preparing 1, 3-Dihydroimidazole-2-Thione Derivatives
LT2919780T (lt) * 2012-11-14 2018-11-12 Bial - Portela & Ca., S.A. 1,3-dihidroimidazol-2-tiono dariniai, skirti panaudoti gydant plautinę arterinę hipertenziją ir plaučių pažeidimą
CN103356671B (zh) * 2013-06-24 2015-11-25 顾祥茂 Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用
GB201316410D0 (en) * 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
AU2018332887B2 (en) 2017-09-13 2022-12-08 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
CA3082337A1 (en) 2017-12-04 2019-06-13 Bial - Portela & Ca, S.A. Dopamine-b-hydroxylase inhibitors
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
IL283047B2 (en) * 2018-11-12 2024-04-01 Immunogen Inc Methods for preparing cytotoxic benzodiazepine derivatives
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
JP2024503906A (ja) * 2021-01-26 2024-01-29 江▲蘇▼▲亞▼虹医▲薬▼科技股▲フン▼有限公司 経路調節因子、それを有する医薬組成物、その使用、及びそれを使用する治療方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1151735A (zh) * 1994-04-26 1997-06-11 辛太克斯(美国)公司 苯并环烷基唑硫酮衍生物
CN1726211A (zh) * 2002-10-11 2006-01-25 坡特拉有限公司 咪唑衍生物及其作为多巴胺－β－羟化酶的周围选择性抑制剂的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1151735A (zh) * 1994-04-26 1997-06-11 辛太克斯(美国)公司 苯并环烷基唑硫酮衍生物
CN1726211A (zh) * 2002-10-11 2006-01-25 坡特拉有限公司 咪唑衍生物及其作为多巴胺－β－羟化酶的周围选择性抑制剂的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Alexandre Beliaev.Synthesis and Biological Evaluation of Novel, Peripherally Selective Chromanyl Imidazolethione-Based Inhibitors of Dopamine β-Hydroxylase.《Journal of Medicinal Chemistry》.2006,第49卷(第3期),全文. *
AlexandreBeliaev.SynthesisandBiologicalEvaluationofNovel Peripherally Selective Chromanyl Imidazolethione-Based Inhibitors of Dopamine β-Hydroxylase.《Journal of Medicinal Chemistry》.2006

Also Published As

Publication number Publication date
AU2008246443A1 (en) 2008-11-13
US20100137390A1 (en) 2010-06-03
US20130345275A1 (en) 2013-12-26
NO20093275L (no) 2010-02-04
DE602008005141D1 (de) 2011-04-07
HK1142898A1 (en) 2010-12-17
ATE499367T1 (de) 2011-03-15
JP5559677B2 (ja) 2014-07-23
IL201921A (en) 2013-11-28
US9630951B2 (en) 2017-04-25
CA2686387A1 (en) 2008-11-13
BRPI0811275A2 (pt) 2014-12-23
US8481582B2 (en) 2013-07-09
US20190322648A1 (en) 2019-10-24
RS51692B (sr) 2011-10-31
RU2009145270A (ru) 2011-06-20
ES2360841T3 (es) 2011-06-09
CY1111517T1 (el) 2015-08-05
BRPI0811275B1 (pt) 2020-01-07
EP2155731B1 (en) 2011-02-23
GB0708818D0 (en) 2007-06-13
SI2155731T1 (sl) 2011-05-31
ZA200908612B (en) 2010-11-24
US20170369478A1 (en) 2017-12-28
WO2008136695A1 (en) 2008-11-13
UA104844C2 (uk) 2014-03-25
BRPI0811275B8 (pt) 2021-05-25
KR20100017546A (ko) 2010-02-16
DK2155731T3 (da) 2011-05-02
PL2155731T3 (pl) 2011-07-29
KR101598482B1 (ko) 2016-02-29
US20210261533A1 (en) 2021-08-26
AU2008246443B2 (en) 2013-07-11
CL2008001321A1 (es) 2008-12-26
IL201921A0 (en) 2010-06-16
HRP20110253T1 (hr) 2011-05-31
JP2010526136A (ja) 2010-07-29
TWI458722B (zh) 2014-11-01
CA2686387C (en) 2015-06-30
CN101687858A (zh) 2010-03-31
RU2501796C2 (ru) 2013-12-20
AR112789A2 (es) 2019-12-11
NZ580962A (en) 2012-05-25
TW200918525A (en) 2009-05-01
AU2008246443A8 (en) 2010-01-07
MX2009012041A (es) 2010-02-18
EP2155731A1 (en) 2010-02-24
AR066457A1 (es) 2009-08-19

Similar Documents

Publication Publication Date Title
CN101687858B (zh) 作为多巴胺-β-羟化酶抑制剂的1,3-二氢咪唑-2-硫酮衍生物
US20090221656A1 (en) Drug Combinations
US10059696B2 (en) Process for preparing 1,3-dihydroimidazole-2-thione derivatives
HK1142898B (en) 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
HK1116188B (en) Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142898

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1142898

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121226